Changes of patient-reported outcomes and protein fingerprint biomarkers after exercise therapy for axial spondyloarthritis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023728%3A_____%2F19%3AN0000033" target="_blank" >RIV/00023728:_____/19:N0000033 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/19:10373377 RIV/00216208:11510/19:10373377

Výsledek na webu

<a href="https://link.springer.com/article/10.1007/s10067-017-3802-7" target="_blank" >https://link.springer.com/article/10.1007/s10067-017-3802-7</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s10067-017-3802-7" target="_blank" >10.1007/s10067-017-3802-7</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Changes of patient-reported outcomes and protein fingerprint biomarkers after exercise therapy for axial spondyloarthritis

Popis výsledku v původním jazyce

The objective of this study was to investigate the patient-reported outcomes (PROs) and matrix metalloproteinase (MMP) derived extracellular matrix (ECM) biomarkers in non-radiographic (nr)-axial spondyloarthritis (axSpA) and radiographic (r)-axSpA after exercise intervention. Forty-six axSpA patients with stable disease and treatment underwent 24weeks long exercise intervention. The clinical and laboratory assessments were performed at baseline and at follow-up. The PROs included evaluation of patient's global disease activity (PGDA), disease activity (DA7), pain (PAIN7) and fatigue during last week and quality of life questionnaires. ELISAs for MMP-degraded collagen type II, C-reactive protein (CRPM) and citrullinated vimentin were used. The data of 23 r-axSpA and 19 nr-axSpA were analysed. The PDGA was similar for nr-axSpA (35.2 +/- 18.9) and r-axSpA (33.4 +/- 22.3) at baseline, improved significantly after intervention (p<0.01) and the change of PDGA was almost identical for nr-axSpA (-10.0 +/- 15.4) and r-axSpA (-9.8 +/- 11.9). Evaluations of DA7 and PAIN7 were significantly improved only in nr-axSpA (3.5 +/- 2.3 and 34.7 +/- 25.6 at baseline vs. 2.1 +/- 1.9 and 21.0 +/- 20.5, respectively, p<0.01). The decline of DA7 and PAIN7 was more profound, but not significantly in nr-axSpA than in r-axSpA (-1.4 +/- 1.6 and -13.7 +/- 17.4 vs. -0.5 +/- 3.1 and -3.7 +/- 3.3, respectively). The quality of life was not changed. At baseline, increased levels of CRPM were found in r-axSpA (14.85 +/- 4.10) compared to nr-axSpA (11.83 +/- 3.20), p<0.05, but all three biomarkers were not influenced by exercise therapy. We found that exercise therapy mainly in the nr-axSpA improves PROs, but not ECM turnover biomarkers. This indicates that exercise therapy is important for patients' health but does not affect ECM turnover.

Název v anglickém jazyce

Changes of patient-reported outcomes and protein fingerprint biomarkers after exercise therapy for axial spondyloarthritis

Popis výsledku anglicky

The objective of this study was to investigate the patient-reported outcomes (PROs) and matrix metalloproteinase (MMP) derived extracellular matrix (ECM) biomarkers in non-radiographic (nr)-axial spondyloarthritis (axSpA) and radiographic (r)-axSpA after exercise intervention. Forty-six axSpA patients with stable disease and treatment underwent 24weeks long exercise intervention. The clinical and laboratory assessments were performed at baseline and at follow-up. The PROs included evaluation of patient's global disease activity (PGDA), disease activity (DA7), pain (PAIN7) and fatigue during last week and quality of life questionnaires. ELISAs for MMP-degraded collagen type II, C-reactive protein (CRPM) and citrullinated vimentin were used. The data of 23 r-axSpA and 19 nr-axSpA were analysed. The PDGA was similar for nr-axSpA (35.2 +/- 18.9) and r-axSpA (33.4 +/- 22.3) at baseline, improved significantly after intervention (p<0.01) and the change of PDGA was almost identical for nr-axSpA (-10.0 +/- 15.4) and r-axSpA (-9.8 +/- 11.9). Evaluations of DA7 and PAIN7 were significantly improved only in nr-axSpA (3.5 +/- 2.3 and 34.7 +/- 25.6 at baseline vs. 2.1 +/- 1.9 and 21.0 +/- 20.5, respectively, p<0.01). The decline of DA7 and PAIN7 was more profound, but not significantly in nr-axSpA than in r-axSpA (-1.4 +/- 1.6 and -13.7 +/- 17.4 vs. -0.5 +/- 3.1 and -3.7 +/- 3.3, respectively). The quality of life was not changed. At baseline, increased levels of CRPM were found in r-axSpA (14.85 +/- 4.10) compared to nr-axSpA (11.83 +/- 3.20), p<0.05, but all three biomarkers were not influenced by exercise therapy. We found that exercise therapy mainly in the nr-axSpA improves PROs, but not ECM turnover biomarkers. This indicates that exercise therapy is important for patients' health but does not affect ECM turnover.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30226 - Rheumatology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

CLINICAL RHEUMATOLOGY

ISSN

0770-3198

e-ISSN

1434-9949

Svazek periodika

38

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

173-179

Kód UT WoS článku

000456957400022

EID výsledku v databázi Scopus

2-s2.0-85028583841